Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone–releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Tri

Degarelix did not improve the PSA nadir response within 6 mo after EBRT in comparison to LHRH agonists, but was associated with lower incidence of CV events among patients with pre-existing CV disease.

Authors

Institutions

Publication Details

Journal
European Urology Oncology
Published
2025-11-08
DOI
https://doi.org/10.1016/j.euo.2025.10.009
Citations
1
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone–releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Tri

Thierry Roumeguère, Pedro C. Lara, J. Jové-Teixidó, I. Latorzeff et al.
1 citations
European Urology Oncology
Prostate Cancer Diagnosis and Treatment
1.52
article

Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone–releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Tri

Thierry Roumeguère, Pedro C. Lara, J. Jové-Teixidó, I. Latorzeff, Andreas Roeder, Bertrand Tombal, Jean-Marc Simon, Thomas Zilli, Dirk Böhmer, Ana Elena Villafranca Iturre, Catherine Fortpied, Piet R. Dirix, David Lauffer, François-Xavier Otte, Béatrice Fournier, Stéphane Supiot, Giulio Francolini
article en
1 citations

Abstract

Degarelix did not improve the PSA nadir response within 6 mo after EBRT in comparison to LHRH agonists, but was associated with lower incidence of CV events among patients with pre-existing CV disease.

European Urology OncologyVol. 8(6)
Cliniques Universitaires Saint-Luc (BE), Université Libre de Bruxelles (BE), Institut Jules Bordet (BE), Copenhagen University Hospital (DK), Sorbonne Université (FR), Universidad Fernando Pessoa Canarias (ES), GZA Ziekenhuizen Campus Sint-Augustinus (BE), Ente Ospedaliero Cantonale (CH), Assistance Publique – Hôpitaux de Paris (FR), Complejo Hospitalario de Navarra (ES), Institut de Cancérologie de l'Ouest (FR), University Hospital of Geneva (CH), Klinik und Poliklinik für Strahlentherapie und Radioonkologie (DE), Azienda Ospedaliero-Universitaria Careggi (IT), Pitié-Salpêtrière Hospital (FR), Universitätsklinik für Strahlentherapie (DE), European Organisation for Research and Treatment of Cancer (BE), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES), Clinique Pasteur (FR), Hospital Universitari Germans Trias i Pujol (ES), University of Florence (IT), Università della Svizzera italiana (CH), Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 13%
Prostate Cancer Diagnosis and Treatment
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.